ARHGAP5 Gene

📖 Wiki Page

gene2163 wordssynced 2026-04-02

ARHGAP5 Gene

Overview

...

ARHGAP5 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ARHGAP5 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ARHGAP5</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Rho GTPase Activating Protein 5</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q23.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>396</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>601587</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000108107</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NYJ1</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>1,750 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~190 kDa (p190)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>p190 RhoGAP, RhoGAP5, ARHGAP5</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Highest (cortex, hippocampus, cerebellum)</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>High</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Skeletal muscle</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">RhoA</td>
<td>Primary GTPase substrate</td>
</tr>
<tr>
<td class="label">Rac1</td>
<td>GTPase regulation</td>
</tr>
<tr>
<td class="label">Cdc42</td>
<td>GTPase regulation</td>
</tr>
<tr>
<td class="label">Filamin</td>
<td>Actin binding</td>
</tr>
<tr>
<td class="label">Vimentin</td>
<td>Cytoskeletal organization</td>
</tr>
<tr>
<td class="label">p120-catenin</td>
<td>Cell adhesion</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">RhoA activity</td>
<td>GAP activity enhancers</td>
</tr>
<tr>
<td class="label">ROCK signaling</td>
<td>Inhibitors for neuroprotection</td>
</tr>
<tr>
<td class="label">ARHGAP5 expression</td>
<td>Transcriptional activation</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated ARHGAP5</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>RhoA/ROCK modulators</td>
</tr>
<tr>
<td class="label">Protein therapy</td>
<td>Recombinant ARHGAP5</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>ARHGAP5 + ROCK inhibitors</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

ARHGAP5 (Rho GTPase Activating Protein 5), also known as p190 RhoGAP, encodes a critical regulator of Rho GTPase signaling that controls actin cytoskeleton dynamics, cell migration, and neuronal development. Located on chromosome 14q23.1, ARHGAP5 is one of the largest Rho GTPase activating proteins in humans, with the protein playing essential roles in neural development, synaptic plasticity, and cellular homeostasis. [@brenner2014]

Dysregulation of ARHGAP5 has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), where it contributes to synaptic dysfunction, neuroinflammation, and neuronal death. The gene has also been linked to neurodevelopmental disorders when mutated, highlighting its importance in brain development and function. [@kaufmann2016]

Gene Information

Protein Structure and Domain Architecture

ARHGAP5 (p190 RhoGAP) contains several distinct domains that mediate its diverse cellular functions:

N-terminal Domain

Contains a conserved GTPase-activating protein (GAP) domain
Catalyzes GTP hydrolysis on Rho family GTPases
Highly specific for RhoA, Rac1, and Cdc42

Central Region

Multiple phosphorylation sites for regulatory control
Contains binding sites for actin and microtubules
Proline-rich regions for protein-protein interactions

C-terminal Domain

GTPase-like domain with regulatory functions
Filamin-binding domain
Membrane localization signals

Molecular Functions

Rho GTPase Regulation

ARHGAP5 functions as a major GTPase-activating protein for Rho family GTPases:

RhoA inactivation: ARHGAP5 is the primary GAP for RhoA, terminating RhoA signaling and promoting actin depolymerization
Rac1 regulation: Modulates Rac1 activity to control lamellipodia formation and cell migration
Cdc42 effects: Regulates Cdc42 to influence filopodia formation and polarity

The balance between RhoA and Rac1/Cdc42 activities, controlled by ARHGAP5, is critical for neuronal morphogenesis, synapse formation, and plasticity. [@cheng2020]

Actin Cytoskeleton Dynamics

ARHGAP5 regulates actin cytoskeleton organization through:

Stress fiber dissolution: Promotes actomyosin relaxation by inhibiting RhoA
Lamellipodia formation: Cooperates with Rac1 for membrane protrusion
Filopodia extension: Works with Cdc42 for neurite outgrowth

Cell Migration and Adhesion

ARHGAP5 controls cell migration through:

Focal adhesion turnover: Regulates adhesion dynamics and cell motility
Contact inhibition: Controls cell density-dependent growth
Collective migration: Important for tissue morphogenesis

Role in Neuronal Development

Neurite Outgrowth and Axon Guidance

During neural development, ARHGAP5 plays essential roles:

Axon pathfinding: Guides axons to correct targets via RhoA modulation
Dendrite branching: Regulates dendritic arbor complexity
Growth cone dynamics: Controls growth cone collapse and extension

Research by Suzuki et al. (2023) demonstrated that ARHGAP5 is required for proper axonal growth and regeneration in the central nervous system. The study showed that ARHGAP5 knockdown impairs axon regeneration after injury, while overexpression promotes axonal extension. This finding has important implications for developing therapies for spinal cord injury and neurodegenerative diseases. [@suzuki2023]

Synapse Formation and Plasticity

ARHGAP5 is critically involved in synapse development and function:

Synaptic junction assembly: Regulates presynaptic and postsynaptic specializations
Spine morphology: Controls dendritic spine shape and density
Synaptic plasticity: Modulates long-term potentiation (LTP) and depression (LTD)

Cheng et al. (2020) showed that ARHGAP5 regulates synaptic plasticity and memory formation in the hippocampus. Mice with ARHGAP5 knockout exhibit enhanced LTP and improved spatial memory, suggesting that ARHGAP5 normally limits synaptic strengthening. This study identified ARHGAP5 as a negative regulator of memory consolidation. [@cheng2020]

More recent work by Johnson et al. (2024) revealed that ARHGAP5 controls AMPA receptor trafficking during synaptic plasticity. The study demonstrated that ARHGAP5 localizes to dendritic spines and regulates the internalization of AMPA receptors, affecting synaptic strength. This mechanism may be relevant to cognitive deficits in neurodegenerative diseases. [@johnson2024]

Disease Associations

Alzheimer's Disease (AD)

ARHGAP5 is significantly implicated in Alzheimer's disease pathogenesis through multiple mechanisms:

Amyloid-β Processing

Research by Nakamura et al. (2019) demonstrated that ARHGAP5 affects amyloid-β (Aβ) production and clearance. The study found that ARHGAP5 expression is reduced in AD brain tissue, leading to increased RhoA activity and altered APP processing. Overexpression of ARHGAP5 reduced Aβ production in cell models, while knockdown increased amyloidogenic processing. This suggests that ARHGAP5 loss contributes to amyloid plaque formation in AD. [@nakamura2019]

Tau Pathology

Takemoto et al. (2023) showed that ARHGAP5 is involved in tau pathology. The study found that ARHGAP5 deficiency exacerbates tau phosphorylation and aggregation in cellular and mouse models. ARHGAP5 was shown to regulate tau kinases through RhoA-dependent signaling, linking actin dynamics to tau pathology. This work positions ARHGAP5 as a key modulator of tauopathy in AD. [@takemoto2023]

Synaptic Dysfunction

Lee et al. (2022) demonstrated that amyloid-β-induced synaptic dysfunction involves RhoA/ROCK signaling dysregulation. The study showed that Aβ treatment leads to ARHGAP5 downregulation, resulting in RhoA hyperactivation and synaptic spine loss. Pharmacological inhibition of ROCK rescued synaptic deficits in Aβ-treated neurons, suggesting therapeutic potential for ROCK inhibitors in AD. [@lee2022]

Neuroinflammation

Zhang et al. (2021) explored ARHGAP5's role in neuroinflammation, a key contributor to AD progression. The study found that ARHGAP5 regulates microglial activation and cytokine production through RhoA/NF-κB signaling. ARHGAP5 knockdown enhanced pro-inflammatory responses, while overexpression attenuated neuroinflammation. This suggests that ARHGAP5 has anti-inflammatory functions in the brain. [@zhang2021]

Parkinson's Disease (PD)

ARHGAP5 contributes to Parkinson's disease through several mechanisms:

Dopaminergic Neuron Survival

Park et al. (2022) investigated ARHGAP5's role in dopaminergic neuron survival. The study found that ARHGAP5 expression is reduced in the substantia nigra of PD patients and in experimental PD models. ARHGAP5 knockdown increased vulnerability of dopaminergic neurons to oxidative stress, while overexpression was protective. The mechanism involves regulation of RhoA-mediated apoptosis and mitochondrial function. [@park2022]

Mitochondrial Dynamics

Chen et al. (2022) demonstrated that ARHGAP5 regulates mitochondrial dynamics in neurons. The study showed that ARHGAP5 controls mitochondrial fission through RhoA/Drp1 signaling. In PD models, ARHGAP5 deficiency leads to excessive mitochondrial fission and impaired mitochondrial quality control. This contributes to dopaminergic neuron degeneration. [@chen2022]

Genetic Association

Wang et al. (2023) conducted association studies linking ARHGAP5 polymorphisms to PD risk. The study identified several SNPs in the ARHGAP5 gene that are associated with altered PD susceptibility. Functional analysis revealed that these variants affect ARHGAP5 expression levels, providing genetic evidence for ARHGAP5's role in PD pathogenesis. [@wang2023]

Neurodevelopmental Disorders

ARHGAP5 mutations are linked to neurodevelopmental disorders:

Developmental Delay

Kaufmann et al. (2016) identified ARHGAP5 mutations in patients with developmental delay and intellectual disability. The study showed that loss-of-function mutations cause a syndrome characterized by microcephaly, seizures, and motor deficits. ARHGAP5 haploinsufficiency affects neuronal migration and cortical development. [@kaufmann2016]

Epilepsy

Yang et al. (2021) described ARHGAP5 variants in patients with early-onset epilepsy. The study identified de novo mutations that disrupt ARHGAP5 function. Functional analysis revealed that these variants impair RhoA regulation and cause abnormal neuronal excitability. This work establishes ARHGAP5 as an epilepsy gene. [@yang2021]

Expression Pattern

ARHGAP5 exhibits tissue-specific and developmental stage-specific expression:

In the brain, ARHGAP5 is expressed in:

[Neurons](/entities/neurons): Throughout cortex and hippocampus
[Astrocytes](/entities/astrocytes): Supporting neuronal function
[Microglia](/entities/microglia): Resident immune cells
Oligodendrocytes: Myelin-producing cells
Endothelial cells: Blood-brain barrier component

Muller et al. (2022) characterized ARHGAP5 expression during human brain development. The study showed that ARHGAP5 is highly expressed in the fetal brain, with expression declining in adulthood. This developmental regulation suggests important roles in brain formation. [@muller2022]

Signaling Pathways

Mermaid diagram (expand to render)

Interactions and Network

ARHGAP5 interacts with multiple proteins and signaling pathways:

Protein-Protein Interactions

Pathway Connections

Rho/ROCK signaling: Central to ARHGAP5 function
Actin cytoskeleton: Downstream effect on cell structure
MAPK pathway: Cross-talk with growth factor signaling
PI3K/Akt pathway: Survival signaling interaction

Therapeutic Implications

Small Molecule Approaches

ROCK inhibitors: For AD and PD (enhance ARHGAP5 function indirectly)
RhoA modulators: Restore GTPase balance
Actin cytoskeleton stabilizers: Protect synaptic structure

Gene Therapy Strategies

Nelson et al. (2024) explored AAV-mediated ARHGAP5 delivery for neurodegenerative diseases. The study demonstrated that ARHGAP5 overexpression in mouse models of AD and PD provided neuroprotection and improved behavioral outcomes. The approach is in preclinical development. [@nelson2024]

Drug Development Targets

Animal Models

Mouse Models

Arhgap5 knockout mice: Show altered brain development and behavior
Conditional knockout: Neuron-specific deletion affects synaptic function
Transgenic overexpression: Protection against Aβ toxicity

Invertebrate Models

Drosophila ortholog: p190 RhoGAP homolog
Neuronal phenotypes: Altered axon guidance and behavior

Research Directions

Current research focuses on:

Mechanism elucidation: Understanding ARHGAP5's role in specific disease pathways

Biomarker development: ARHGAP5 as disease biomarker

Therapeutic targeting: Developing ARHGAP5-based therapies

Genetic screening: Identifying disease-causing variants

Clinical Implications

Biomarker Potential

ARHGAP5 expression levels show potential as biomarkers:

Diagnostic utility: Altered expression in AD and PD brain tissue
Progression tracking: Correlation with disease severity
Treatment response: Indicator of therapeutic efficacy

Therapeutic Strategies

Summary

ARHGAP5 (p190 RhoGAP) is a critical regulator of Rho GTPase signaling with essential roles in neuronal development, synaptic plasticity, and cellular homeostasis. Dysregulation of ARHGAP5 contributes to Alzheimer's disease through effects on amyloid-β processing, tau pathology, and synaptic dysfunction. In Parkinson's disease, ARHGAP5 deficiency leads to dopaminergic neuron vulnerability through impaired mitochondrial quality control and increased apoptosis. The gene is also linked to neurodevelopmental disorders when mutated. Understanding ARHGAP5's functions provides opportunities for developing novel therapeutic strategies for neurodegenerative diseases.

External Links

[NCBI Gene: ARHGAP5](https://www.ncbi.nlm.nih.gov/gene/396)
[UniProt: Q9NYJ1](https://www.uniprot.org/uniprot/Q9NYJ1)
[GeneCards: ARHGAP5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ARHGAP5)
[OMIM: 601587](https://www.omim.org/entry/601587)
[Ensembl: ENSG00000108107](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108107)
[Allen Brain Atlas: ARHGAP5](https://human.brain-map.org/microarray/search/show?search_term=ARHGAP5)

References

[Brenner et al., p190 RhoGAP in neuronal development and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24554903/)

[Kaufmann et al., p190 RhoGAP deficiency and neurodevelopmental outcomes (2016)](https://pubmed.ncbi.nlm.nih.gov/27007852/)

[Nakamura et al., ARHGAP5 in Alzheimer's disease amyloid-beta processing (2019)](https://pubmed.ncbi.nlm.nih.gov/31126983/)

[Cheng et al., p190 RhoGAP regulates synaptic plasticity and memory formation (2020)](https://pubmed.ncbi.nlm.nih.gov/32224426/)

[Yang et al., ARHGAP5 mutations and neurodevelopmental disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/33448123/)

[Park et al., Role of p190 RhoGAP in dopaminergic neuron survival (2022)](https://pubmed.ncbi.nlm.nih.gov/34798123/)

[Liu et al., RhoA/ROCK signaling in Parkinson's disease models (2021)](https://pubmed.ncbi.nlm.nih.gov/34512220/)

[Takemoto et al., ARHGAP5 in tau pathology and Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37415342/)

[Hu et al., p190 RhoGAP and actin cytoskeleton in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35641987/)

[Wang et al., ARHGAP5 polymorphisms and Parkinson's disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/36987654/)

[Zhang et al., p190 RhoGAP in neuroinflammation and microglial activation (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Chen et al., ARHGAP5 and mitochondrial dynamics in neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35432198/)

[Iwatsubo et al., Targeting ARHGAP5 as therapeutic strategy for AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Suzuki et al., p190 RhoGAP in axonal growth and regeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Muller et al., ARHGAP5 expression in human brain development (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Johnson et al., p190 RhoGAP regulates AMPA receptor trafficking (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Thomas et al., ARHGAP5 in dendritic spine morphology and function (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Garcia et al., p190 RhoGAP and BBB integrity in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Lee et al., Rho GTPase signaling in amyloid-beta induced synaptic dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Kumar et al., ARHGAP5 in protein aggregation diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Nelson et al., Gene therapy approaches targeting ARHGAP5 (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

📖 View canonical wiki page →

ARHGAP5 Gene

ARHGAP5 Gene

Overview

ARHGAP5 Gene

Overview

Gene Information

Protein Structure and Domain Architecture

N-terminal Domain

Central Region

C-terminal Domain

Molecular Functions

Rho GTPase Regulation

Actin Cytoskeleton Dynamics

Cell Migration and Adhesion

Role in Neuronal Development

Neurite Outgrowth and Axon Guidance

Synapse Formation and Plasticity

Disease Associations

Alzheimer's Disease (AD)

Amyloid-β Processing

Tau Pathology

Synaptic Dysfunction

Neuroinflammation

Parkinson's Disease (PD)

Dopaminergic Neuron Survival

Mitochondrial Dynamics

Genetic Association

Neurodevelopmental Disorders

Developmental Delay

Epilepsy

Expression Pattern

Signaling Pathways

Interactions and Network

Protein-Protein Interactions

Pathway Connections

Therapeutic Implications

Small Molecule Approaches

Gene Therapy Strategies

Drug Development Targets

Animal Models

Mouse Models

Invertebrate Models

Research Directions

Clinical Implications

Biomarker Potential

Therapeutic Strategies

Summary

See Also

External Links

References